This finding suggests that GATA4 agonist(s), such as phenylephrine, could be developed to treat hyperlipidemia, and exploring the transcriptomic change affected by phenylephrine would be crucial to understand the possible therapeutic action through GATA4 activity. Here, GATA4 is linked to hyperlipidemia.